The efficacy of RNAdjuvant® to enhance antigen-specific CD8+ T-cell responses and to mediate anti-tumour responses was demonstrated in the syngeneic TC-1 tumour, a murine model of human papillomavirus (HPV)-induced cervical cancer. Here, CD8A is linked to neoplasm.